Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

Benzinga

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Benzinga

Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%

The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS).

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc (NASDAQ:AFRM) is a buy. “It's at $72, it's going to $100,” he noted.

Benzinga

Government partners with Mounjaro maker to tackle obesity

The £85 million programme will looks at ways for patients to access services more easily.

Evening Standard

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Co. Q2 FY2025 Earnings Transcript

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Shares fall after weight loss pill disappoints in trial

IN FULL

The Independent UK

Eli Lilly will seek approval for experimental weight loss pill after promising study

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Euronews

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

Evening Standard

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

Benzinga

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The Guardian - US

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

The Independent UK

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

Benzinga

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Euronews

EU regulator backs new Alzheimer’s treatment, reversing initial decision to reject it

An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s disease.

Kiplinger

Wellness Stocks to Invest in Now

Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

LiveScience

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific cholesterol-raising conditions.

Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

MarketBeat

Are Growth Stocks Back? 3 That Look Like Winners to Buy Now

Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.